Press Releases

Press Releases

View all news
Voronoi Licenses Out Lung Cancer Therapy to ORIC in the U.S. in KRW 720 Billion Deal
2020.10.20
⚫ Treatment for EGFR/HER2 Exon20 ins. mutation lung cancer and solid tumors
⚫ Precision targeted drug capable of treating even brain metastases
⚫ KRW 720 billion license-out to NASDAQ-listed ORIC in the U.S.

Voronoi, a company specializing in the development of precision targeted therapies, announced on the 20th that it has signed an agreement to license out its in-house developed drug candidate for EGFR (epidermal growth factor receptor)/HER2 (human epidermal growth factor receptor 2) Exon20 insertion mutation non-small cell lung cancer (NSCLC) and solid tumors to ORIC Pharmaceuticals, a NASDAQ-listed U.S. company. The upfront payment is USD 13 million, and the total deal size is up to USD 621 million, equivalent to approximately KRW 720 billion. Upon final commercialization, Voronoi will receive annual royalties of around 10%. Under the agreement, ORIC obtains global rights excluding Greater China (China, Hong Kong, Macau, and Taiwan) and plans to begin Phase 1/2 clinical trials in the second half of next year. Currently, there is no therapy that specifically targets non-small cell lung cancer caused by Exon 20 insertion mutations.

Voronoi's lung cancer drug candidate is expected to deliver excellent therapeutic efficacy because it acts with very high precision and selectivity only on the Exon 20 insertion mutation that causes the cancer. It also has far higher brain penetrance than competing lung cancer drug candidates. Among patients with Exon 20 insertion mutation lung cancer, 30–40% suffer from brain metastases, and successful commercialization is expected to offer them hope. As an oral therapy, it also offers a high level of patient convenience.

CEO Daekwon Kim of Voronoi said, "We are pleased to join hands with ORIC, whose team members have extensive experience in developing targeted therapies. We hope the day will come as soon as possible when patients who suffer through conventional chemotherapy for lack of a targeted therapy can receive proper treatment."

Jacob Chacko, CEO of ORIC, said, "We are delighted to add a new pipeline program to ORIC, which has expertise in precision oncology. We will be able to make good use of our prior experience in developing entrectinib, a treatment for ROS1 mutation non-small cell lung cancer." He added, "Voronoi's highly selective and highly brain-penetrant therapy will benefit patients who have gone untreated until now."

ORIC is a NASDAQ-listed pharmaceutical company based in California, U.S., founded in 2014 by executives with experience at global big pharma companies such as Roche, Pfizer, Genentech, and Biogen, who have succeeded in developing anticancer drugs for non-small cell lung cancer, prostate cancer, and other indications. Ignyta, previously founded by ORIC's core executives, developed entrectinib, a treatment for ROS1 mutation non-small cell lung cancer, and was acquired by Roche for USD 1.7 billion in 2018. ORIC is currently developing targeted therapies for prostate cancer

and other solid tumors.